Semaglutide (SEMA)

GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Brand names include Ozempic and Wegovy.

Key Data

Research Status

FDA approved

Half-Life

~7 days

Administration

Subcutaneous injection

Typical Dosage

0.25-2.4 mg weekly

Mechanism of Action

GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity.

Reported Benefits

• Significant weight loss
• Blood sugar control
• Cardiovascular benefits
• Appetite reduction

All information is presented for Research Use Only (RUO). Not medical advice.